Bleakley Financial Group LLC Cuts Position in Moderna, Inc. (NASDAQ:MRNA)

Bleakley Financial Group LLC lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 24.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,349 shares of the company’s stock after selling 1,062 shares during the period. Bleakley Financial Group LLC’s holdings in Moderna were worth $333,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MRNA. First Pacific Financial purchased a new position in shares of Moderna in the 3rd quarter valued at about $27,000. ICA Group Wealth Management LLC purchased a new stake in Moderna during the 4th quarter worth approximately $27,000. Arlington Trust Co LLC increased its stake in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares in the last quarter. Stonebridge Capital Advisors LLC increased its stake in Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after buying an additional 125 shares in the last quarter. Finally, Ancora Advisors LLC increased its stake in Moderna by 41.2% during the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after buying an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the transaction, the director now directly owns 2,071,931 shares in the company, valued at $221,945,248.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO James M. Mock sold 705 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the sale, the chief financial officer now owns 5,048 shares of the company’s stock, valued at $514,542.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $107.12, for a total value of $1,606,800.00. Following the sale, the director now directly owns 2,071,931 shares in the company, valued at approximately $221,945,248.72. The disclosure for this sale can be found here. Insiders have sold 94,954 shares of company stock worth $9,966,476 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Moderna Trading Down 1.7 %

MRNA opened at $105.14 on Monday. Moderna, Inc. has a one year low of $62.55 and a one year high of $163.24. The stock has a market capitalization of $40.26 billion, a PE ratio of -8.47 and a beta of 1.62. The business’s 50 day moving average price is $99.86 and its 200 day moving average price is $93.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same period in the prior year, the firm posted $3.61 earnings per share. The firm’s quarterly revenue was down 44.9% on a year-over-year basis. As a group, equities research analysts expect that Moderna, Inc. will post -7.48 EPS for the current year.

Analysts Set New Price Targets

MRNA has been the subject of several research reports. Canaccord Genuity Group boosted their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday. Finally, HSBC restated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.